Published in Postgrad Med J on January 01, 1977
Selective blockade of adrenoceptive beta receptors in the heart. Br J Pharmacol Chemother (1968) 14.80
Comparison of some properties of pronethalol and propranolol. Br J Pharmacol Chemother (1965) 4.71
Comparison of the effects of I.C.I. 50172 and propranolol on the cardiovascular responses to adrenaline, isoprenaline and exercise. Br J Pharmacol (1968) 4.20
Acute phase of myocardial infarction. Lancet (1971) 4.05
The pharmacology of beta sympathetic blockade. Am J Cardiol (1966) 3.96
Quantitative trait loci on chromosomes 3 and 17 influence phenotypes of the metabolic syndrome. Proc Natl Acad Sci U S A (2000) 3.44
Clinical pharmacologic observations on atenolol, a beta-adrenoceptor blocker. Clin Pharmacol Ther (1976) 3.16
Optical isomers of propranolol. Nature (1966) 3.09
Management of ventricular fibrillation outside hospital. Lancet (1969) 3.07
The cardio-toxicity of isoprenaline during hypoxia. Br J Pharmacol (1969) 2.94
The clinical pharmacology of mexiletine. Br J Clin Pharmacol (1978) 2.56
Controlled trial of propranolol in thyrotoxicosis. Lancet (1969) 2.54
The effect of propranolol on the cardiovascular responses to isoprenaline, adrenaline and noradrenaline in the anaesthetized dog. Br J Pharmacol Chemother (1966) 2.52
Cardio-selective beta-blockade. Naunyn Schmiedebergs Arch Exp Pathol Pharmakol (1968) 2.33
Laparoscopic dismembered pyeloplasty: 50 consecutive cases. BJU Int (2001) 2.21
The effect of Kö 1173, a new anticonvulsant agent on experimental cardiac arrhythmias. Br J Pharmacol (1972) 2.11
The clinical pharmacology of beta adrenergic blocking drugs. J R Coll Physicians Lond (1976) 1.94
National Poisons Information Services: report and comment 1980. Br Med J (Clin Res Ed) (1981) 1.91
Oral mexiletine in high-risk patients after myocardial infarction. Lancet (1981) 1.91
The peripheral vascular effects of propranolol and related compounds. Br J Pharmacol Chemother (1967) 1.87
The effect of experimental cardiac arrhythmias of a new anticonvulsant agent, Kö 1173, and its comparison with phenytoin and procainamide. Br J Pharmacol (1970) 1.81
Blood levels of practolol after oral and parenteral administration and their relationship to exercise heart rate. Clin Pharmacol Ther (1974) 1.81
Influence of intrinsic sympathomimetic activity and cardioselectivity on beta adrenoceptor blockade. Clin Pharmacol Ther (1977) 1.77
Observations on the efficacy and pharmacokinetics of sotalol after oral administration. Eur J Clin Pharmacol (1976) 1.71
Mexiletine (Kö 1173) in the management of ventricular dysrhythmias. Lancet (1973) 1.68
Diffuse interstitial pneumonitis. Clinicopathologic correlations in 20 patients treated with prednisone/azathioprine. Am J Med (1978) 1.67
Clinical pharmacokinetics of oral anticoagulants. Clin Pharmacokinet (1979) 1.66
Some pharmacological properties of a new adrenergic beta-receptor antagonist. Nature (1966) 1.66
Effects of the beta 2-adrenoceptor antagonist ICI 118,551 on exercise tachycardia and isoprenaline-induced beta-adrenoceptor responses in man. Br J Clin Pharmacol (1985) 1.65
Propranolol and the utilization of radioiodine by the human thyroid gland. Acta Endocrinol (Copenh) (1969) 1.63
Effect of propranolol on arrhythmias following coronary artery occlusion in dogs. Cardiovasc Res (1967) 1.61
Neonatal thyrotoxicosis treated with propranolol. Arch Dis Child (1974) 1.59
Comparison of the activity and plasma levels of oxprenolol, slow release oxprenolol, long acting propranolol and sotalol. Eur J Clin Pharmacol (1980) 1.57
Comparison of the efficacy and pharmacokinetics of conventional propranolol and a long acting preparation of propranolol. Br J Clin Pharmacol (1980) 1.55
Stimulation of adrenergic beta-receptors by orciprenaline. Br Med J (1967) 1.52
Plasma digoxin concentrations in patients on admission to hospital. Br Heart J (1974) 1.46
Debendox and congenital malformations in Northern Ireland. Br Med J (1980) 1.46
Frequency analysis of ventricular fibrillation and resuscitation success. Q J Med (1992) 1.46
Clinical pharmacology methodology: introduction. Br J Clin Pharmacol (1978) 1.39
Pharmacokinetics of enalapril in normal subjects and patients with renal impairment. Br J Clin Pharmacol (1986) 1.38
Comparison of the effect of propranolol, lignocaine, and other drugs on normal and raised intraocular pressure in man. Am J Ophthalmol (1971) 1.37
Spectrophotofluorometric and gas-liquid chromatographic methods for the estimation of mexiletine (Kö 1173) in plasma and urine. J Pharm Pharmacol (1973) 1.36
Duration of action of beta-blocking drugs. Br Med J (1973) 1.33
Beliefs about Papanicolaou smears and compliance with Papanicolaou smear follow-up in adolescents. Arch Pediatr Adolesc Med (1999) 1.33
Effects of alinidine, a novel bradycardic agent, on heart rate and blood pressure in man. J Cardiovasc Pharmacol (1982) 1.32
Measurement of theophylline in plasma by high performance liquid chromatography. Br J Clin Pharmacol (1976) 1.31
Propranolol and iodine-131 in the management of thyrotoxicosis. Lancet (1968) 1.29
Effects of partial extraction of troponin complex upon the tension-pCa relation in rabbit skeletal muscle. Further evidence that tension development involves cooperative effects within the thin filament. J Gen Physiol (1986) 1.29
Measurement of plasma mexiletine concentrations. Postgrad Med J (1977) 1.28
Stimulation of gastrin release by catecholamines. Lancet (1972) 1.26
Hereditary alpha-1-antitrypsin deficiency. N Engl J Med (1968) 1.26
Comparison of the effects of propranolol and MJ 1999 on cardiac beta-adrenoceptors in man. Br J Pharmacol (1970) 1.24
Effects on exercise tachycardia during forty-eight hours of a series of doses of atenolol, sotalol, and metoprolol. Clin Pharmacol Ther (1981) 1.23
Theophylline kinetics in relation to age: the importance of smoking. Br J Clin Pharmacol (1980) 1.23
Breast cancer resistance protein is localized at the plasma membrane in mitoxantrone- and topotecan-resistant cell lines. Cancer Res (2000) 1.21
Using a pharmacogenomic algorithm to guide the treatment of depression. Transl Psychiatry (2012) 1.19
Effects of the myocardial-selective alpha 1-adrenoceptor antagonist UK-52046 and atenolol, alone and in combination, on experimental cardiac arrhythmias in dogs. Br J Pharmacol (1988) 1.17
Sources of control over schedule-induced drinking produced by second-order schedules of reinforcement. Physiol Behav (1977) 1.17
Cardiovascular effects of alinidine and propranolol alone and in combination with hydralazine in normal man. Br J Clin Pharmacol (1983) 1.16
Is Apaf-1 expression frequently abrogated in melanoma? Cell Death Differ (2005) 1.15
Schedule-induced drinking as a function of percentage reinforcement. J Exp Anal Behav (1975) 1.14
Correlation of reduction of exercise heart rate with blood levels of atenolol after oral and intravenous administration. Postgrad Med J (1977) 1.13
Schedule-induced drinking as a function of interreinforcement interval in the rhesus monkey. J Exp Anal Behav (1976) 1.11
Is verapamil a beta-blocker? Lancet (1968) 1.11
The role of the thyroid in the control of heart-rate. Lancet (1968) 1.10
The development of mexiletine in the management of ventricular dysrhythmias. Postgrad Med J (1977) 1.09
Why medical students will not practice in rural areas: evidence from a survey. Soc Sci Med (1986) 1.09
The pharmacokinetics of vincristine in man: reduced drug clearance associated with raised serum alkaline phosphatase and dose-limited elimination. Cancer Chemother Pharmacol (1982) 1.08
Psychiatric pharmacogenomics predicts health resource utilization of outpatients with anxiety and depression. Transl Psychiatry (2013) 1.07
Alinidine reduces heart-rate without blockade of beta-adrenoceptors. Lancet (1981) 1.06
Do patients take digoxin? Br Heart J (1978) 1.06
Effects of lignocaine and propranolol on experimental cardiac arrhythmias. Br J Pharmacol (1971) 1.04
Rounded biphasic waveform reduces energy requirements for transvenous catheter cardioversion of atrial fibrillation and flutter. Pacing Clin Electrophysiol (1997) 1.03
Characterization of the beta-adrenoreceptors which mediate the isoprenaline-induced changes in finger tremor and cardiovascular function in man. Eur J Clin Pharmacol (1988) 1.03
Rating the urgency of coronary angiography: results of an expert panel process. Ontario Coronary Angiography Panel. Can J Cardiol (1993) 1.02
Death and damage caused by multiple direct current shocks: studies in an animal model. Eur Heart J (1988) 1.02
Effects of ICI 141,292 on exercise tachycardia and isoprenaline-induced beta-adrenoceptor responses in man. Br J Clin Pharmacol (1986) 1.01
The effect of the dextro isomer of propranolol on sinus rate and cardiac arrhythmias. Am Heart J (1968) 1.01
Significance of blood lactate levels in critically ill patients with liver disease. Am J Med (1987) 1.01
Observation on the efficacy and pharmacokinetics of betaxolol (SL 75212), a cardioselective beta-adrenoceptor blocking drug. Br J Clin Pharmacol (1981) 1.00
Comparison of the effects of isoprenaline, orciprenaline, salbutamol and isoetharine on the cardiovascular system of anaesthetized dogs. Br J Pharmacol (1971) 1.00